Core Insights - Baicheng Pharmaceutical (301096) has entered into an exclusive collaboration with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [2] - The collaboration agreement will become effective upon approval by the company's shareholders [2] - Baicheng Pharmaceutical will be responsible for the research and development, clinical trials, and registration of the product, while Zhongshen Innovative will handle the R&D transformation, production, sales, and market expansion in the Greater China region [2] - Following the signing of the contract, Zhongshen Innovative will pay milestone payments of 300 million yuan based on R&D milestones [2] - After the product is launched in the Greater China region, Baicheng Pharmaceutical will receive a 10% commission on sales revenue [2]
百诚医药BIOS-0629项目签署技术开发合作协议